Industry Overview
The U.S. electrotherapy market size was estimated at USD 480.31 million in 2024 and is anticipated to reach USD 693.90 million by 2033, expanding at a CAGR of 4.24% from 2025 to 2033. This growth is attributed to the increasing prevalence of chronic pain, musculoskeletal disorders, and sports-related injuries, which have driven demand for non-invasive and drug-free pain management solutions.
Business Description
The Company offers a comprehensive portfolio of non-invasive electro-therapy products and related DME solutions designed to improve patient outcomes and support pain management and rehabilitation. The Company’s products are tailored for home use and are supported by an efficient fulfillment and pre-authorization process that enhances accessibility and convenience for both physicians and patients. Digital TENS/EMS units for customizable pain relief.
Financial Summary
Financial Overview
The Company’s revenue has increased significantly from 2022 to 2025 at a compounded annual growth rate (CAGR) of 84% while achieving a 34% adjusted EBITDA margin. The Company expects to continue its double-digit growth rates from a strong first quarter of new patients in 2026. Total 2026 revenues are forecasted to grow to $2.9 million and $1.1 million in Adjusted EBITDA (38%).
Investment Rationale
Some key attributes of this Company include the following:
• Strong physician and therapist referral network driving consistent revenue
• Customized, easy-to-use electro-therapy devices that support at-home patient care
• High revenue growth of 84% CAGR over 3 years
• Strong Adjusted EBITDA Margins of 38% and Gross Profit Margin of 77%
• April 2026 LTM adjusted EBITDA of $925,000
Customer Overview
The Company’s payer mix consists entirely of Commercial Insurance, with no Medicare or Medicaid exposure. To support efficient reimbursement operations, the Company utilizes third-party billing services and established insurance networks.
The payer mix is composed of the following:
• Blue Cross Blue Shield – Texas: 53%
• United Health and Federal Blue Cross Blue Shield: 38%
• Blue Cross Blue Shield – Arkansas: 9%
Staff Overview
Staff Overview
The Company’s team is expected to remain in place under new ownership, including 8 employees and 7 independent contractors.
Asking Price
Asking Price
The asking price is $9 Million plus an earn-out going forward. The Seller will consider a majority sale and rollover of equity while remaining involved post-close. This does not include cash, receivables, or working capital.
To register interest you will need to complete our Buyer Verification Process.
